Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.

Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.

Abstract: Pharmaceiiticai compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.

Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.

Abstract: Synergistic pharmaceutical compositions including an RNase P inhibitor and a tRNA synthetase inhibitor are provided, as well as methods for their use in treating infections. Also provided herein are methods of using the compositions to inhibit a bacterial tRNA synthetase in a cell and to decolonize bacteria on a surface.

Abstract: The present invention relates to biomimetic scaffolds, methods for making the same, and methods for using the same. The scaffolds comprise a plurality of graded or tapered microchannels that provide spatial control for cell penetration. The scaffolds are useful for regenerating missing interface tissue between two adjacent tissues, or regeneration and integration of two adjacent tissues directly.

Abstract: The present invention relates to compositions comprising ionic compounds surrounded by organic matrices, and methods for producing such compositions. In various embodiments, the compositions of the present invention are co-crystals of an organic compound and a salt. The organic compound forms matrices with channel structures, wherein the organic matrices interact relatively poorly with the salt, thus allowing for excellent ion mobility through the channel structures. In one embodiment, the compositions are soft-solid electrolytes, comprising ions such as lithium or sodium, which can be used in batteries or other electrochemical devices. The electrolyte compositions of the present invention exhibit relatively high ionic conductivities with a negligible activation barrier for ion migration, i.e., the compositions exhibit barrierless ion conduction. In addition, the compositions exhibit good conductivities at very low temperatures, making them useful in a variety of low temperature applications.

Abstract: A tactile sensor, computer readable medium, methods of using and manufacturing the tactile sensor, and methods and apparatuses for processing the information generated by the tactile sensor. The tactile sensor includes a planar optical waveguide comprised of a flexible and transparent layer; a light configured to direct light into the optical waveguide; a light sensor or an imager facing the optical waveguide and configured to generate signals from light scattered out of the optical waveguide; and a controller which may be configured to generate an image of the object and characteristics of the object. The waveguide may be configured so that some of the light directed into the optical waveguide is scattered out of the waveguide if the waveguide is deformed by being pressed against the object. A finite element and a neural network are used to estimate mechanical characteristics of the objects.

Abstract: The dynamic positioning of sensors, which exploit the mechanical and physiological changes in tissues, can significantly increase the performance in characterization of tumors. Here, we disclose the Optical Dynamic Imaging (ODI) System for tumor characterization. ODI System estimates size, depth, elastic modulus and optical properties of embedded objects. The ODI System consists of a tactile imaging sensor (TIS), and a near infrared diffuse spectral imaging. To obtain mechanical properties of the target, we compress the region of interest with the probe, then the light from the probe is scattered and captured by the camera as a tactile image. On the other hand, using a light source and the camera as a detector, we obtain the diffuse spectral images. From these images, we compute the absorption coefficient of the embedded tumor phantom. We move the source-detector simultaneously and collect optical information. We termed this maneuver as dynamic positioning.

Abstract: Compositions are directed to BCL2-associated athanogene 3 (BAG3) molecules and agents which modulate expression of BAG3 molecules. Pharmaceutical composition for administration to patients, for example, patients with heart failure, comprise one or more BAG3 molecules or agents which modulate expression of BAG3. Methods of treatment and identifying candidate therapeutic agents are also provided.

Abstract: Methods are presented for the therapeutic administration of angiocidin in the treatment of cancers such as glioma, breast cancer, and leukemia. Methods are also presented for inducing growth arrest and/or apoptosis of tumor cells, as well as inducing differentiation of tumor cells to inhibit tumorigenicity and to confer a non-tumor or healthy phenotype.

Abstract: The present disclosure provides an antimicrobial composition including a compound which is a biscationic or triscationic amphiphile, and the method of making such an antimicrobial composition, and the method of using such a compound or composition for antimicrobial use. The antimicrobial composition can include a compound having the formula (I) wherein R is a methylene group unsubstituted or optionally substituted, s is an integer in the range from 1 to 6, R1, R2, R3 or R4 is H or a C1-4 alkyl unsubstituted or optionally substituted, X is a halogen, m and n are integers in the range from 5 to 25, and m is not equal to n. Alternatively, the antimicrobial composition can comprise a compound having the formula (III) or (IV) wherein R1, R2, R3, R4 R5, or R6 is H or a C1-4 alkyl unsubstituted or optionally substituted, X or Y is a halogen, and m and n are integers in the range from 5 to 25.

Abstract: The present disclosure provides an antimicrobial composition including a polycationic amphiphile compound, and the method of making and the method of using such a compound or composition. The compound having the formula (I) or (II) R1, R2, R3, R4, R5, R6, R10, or R11 is H or a C1-12 alkyl unsubstituted or optionally substituted with a functional group such as —OH, —OR?, —NH2, —NHR?, —NR?2, —N—C(0)R?, —N—C(0)CR??CR?, —SH, —SR?, -0-C(0)R?, —C(0)R?, —CF3, —OCF3, halogen, benzyl, o-vinylbenzyl, m-vinylbenzyl, p-vinylbenzyl, phenyl, allyl, and substituted allyl. R7, R8 or R9 is a C1-12 alkyl unsubstituted or optionally substituted with a functional group such as —OH, —OR?, —NH2, —NHR?, —NR?2, —SH, —SR?, -0-C(0)R?, —C(0)R?, —CF3, and —OCF3. R? is H or a C1-4 alkyl. X or Y is a halogen, m and n are integers in the range from 1 to 25.

Abstract: A method of inactivating a proviral DNA integrated into the genome of a host cell latently infected with a retrovirus by treating the host cell with a composition comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, and two or more different guide RNAs (gRNAs), wherein each of the at least two gRNAs is complementary to a different target nucleic acid sequence in a long terminal repeat (LTR) in the proviral DNA, and inactivating the proviral DNA. A composition for use in inactivating a proviral DNA integrated into the genome of a host cell latently infected with a retrovirus including isolated nucleic acid sequences comprising a CRISPR-associated endonuclease and a guide RNA, wherein the guide RNA is complementary to a target sequence in a human immunodeficiency virus.

Abstract: The present disclosure provides an antimicrobial composition including a polycationic amphiphile compound, and the method of making and the method of using such a compound or composition. The compound having the formula R1, R2, R3, R4, R5, R6, R10, or R11 is H or a C1-12 alkyl unsubstituted or optionally substituted with a functional group such as —OH, —OR?, —NH2, —NHR?, —N—C(O)R?, —N—C(O)CR??CR?, —SH, —SR?, —O—C(O)R?, —C(O)R?, —CF3, —OCF3, halogen, benzyl, o-vinylbenzyl, m-vinylbenzyl, p-vinylbenzyl, phenyl, allyl, and substituted allyl. R7, R8 or R9 is a C1-12 alkyl unsubstituted or optionally substituted with a functional group such as —OH, —OR?, —NH2, —NHR?, —SH, —SR?, —O—C(O)R?, —C(O)R?, —CF3, and —OCF3. R? is H or a C1-4 alkyl. X or Y is a halogen. m and n are integers in the range from 1 to 25.

Abstract: The present invention includes a robotic system for the enhanced automation, manipulation, and control of electroprocessing in two or three dimensions. In one embodiment, the system includes a sealed chamber devoid of any electrical or conductive components which would interfere with the electrical field and eventual material fabrication, while still allowing for two-dimensional and three-dimensional robot motion. In certain embodiments, the system of the invention produces materials or scaffolds with complex shapes, including materials with ridges, valleys, curves, and the like, which are difficult or impossible to construct using traditional systems.

Abstract: Compositions include nucleic acid sequences encoding the C-terminal fragment of fragment (Seg3) of Nuclear factor-erythroid 2 related factor 2 (Nrf2). These compositions provide a target for identification of novel therapeutics having the ability to modulate the translation of Nrf2. Methods of treating subjects are also provided.

Abstract: Small molecule inhibitors of bacterial ribonuclease (e.g., RnpA) and methods for their synthesis and use are described herein. The methods of using the compounds include treating and preventing microbial infections and inhibiting bacterial ribonuclease. Also described herein are methods of identifying compounds for treating or preventing a microbial infection.

Abstract: An apparatus (100) for reducing the size of fuel particles injected into a combustion chamber is disclosed. The apparatus includes fuel line (110), a first metallic mesh (114) disposed within the fuel line (110), and a second metallic mesh (112) disposed within the fuel line (110), upstream of the first metallic mesh (114). An electrical supply (130) is electrically coupled to the first metallic mesh (114) and the second metallic mesh (112). Operation of the electrical supply (130) generates an electrical field between the first metallic mesh (114) and the second metallic mesh (112). A fuel injector (120) is disposed at an end of the fuel line (110), downstream from the first metallic mesh (114). Methods of reducing the size of fuel particles, improving gas mileage in a vehicle, increasing power output from a combustion engine, and improving emissions for a combustion engine are also provided.

Abstract: An embodiment of the invention relates to the use of stabilized cancer peptide fragments derived from “redoxin proteins” selected from the group consisting of thioredoxin; peroxiredoxin-1, 2 and 3; glutaredoxin-3; glutathione peroxidase-4; and nucleoredoxins for the diagnosis of cancers, particularly pancreatic cancer. A method for the detection of cancer, severity of cancer, and/or effectiveness of a therapeutic regimen comprises detecting and/or measuring the amount of redoxin peptide fragments present in the biological sample of a subject.